Revvity Inc vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Revvity Inc trades at $154.18 (market cap $16.98B), while Vanguard Total Stock Market Index Fund ETF trades at $381.94 (market cap $2.30T). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 135.5× Revvity Inc's market cap, and Revvity Inc pays a 0.18% dividend while Vanguard Total Stock Market Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Vanguard Total Stock Market Index Fund ETF for 131 Days on average.
| RVTY | VTI | |
|---|---|---|
Market Cap | $16.98B | $2.30T |
Volume | 1,456,900 | 2,982,924 |
Sector | Health | — |
52-Week High | $157.36 | $384.30 |
52-Week Low | $82.26 | $311.68 |
Typical Hold Time | 12 Days | 131 Days |
Enterprise Value | $19.30B | — |
Dividend Yield | 0.18% | — |
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
VTI trades at $379.56, down 0.39% on the day, with a bullish technical signal driven by moving averages. The ETF provides broad U.S. equity exposure, though key valuation and profitability ratios are not publicly disclosed for the fund itself. Recent news highlights its role in diversified portfolios and long-term growth potential.
The outlook for VTI remains positive given its low-cost, diversified structure and historical performance. Risks include market concentration in top holdings and broader economic volatility. Analyst sentiment is generally favorable for long-term investors seeking total market exposure.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →